A-share IPO subscription | Aide Technology (920180.BJ) starts subscription, mainly engaged in the research, development, production, and sales of medical devices, with orthopedic consumables as the main focus.

On February 2nd, AiDe Technology (920180.BJ) started its IPO, with an issue price of 7.67 yuan per share and a maximum subscription limit of 1.3288 million shares. The industry's price-earnings ratio is 14.98 times, and it belongs to the Beijing Stock Exchange, with Debang Securities as its sponsoring institution. According to the prospectus, AiDe Technology is mainly engaged in the research, development, production, and sales of medical devices, primarily focusing on orthopedic consumables. Its main products include orthopedic medical consumables such as spine, trauma, sports medicine, and wound repair products. The company adheres to the clinical needs of orthopedics and aims to become a leading provider of comprehensive orthopedic surgical solutions covering all fields in the orthopedic industry. With over ten years of experience in the orthopedic medical device industry, the company has always been focused on the clinical needs of end users, providing integrated surgical solutions based on clinical medical pain points. Initially, the company followed the principle of minimizing iatrogenic injuries in surgery, taking into consideration the characteristics of the aging orthopedic chronic disease population, and providing minimally invasive treatment solutions including vertebral augmentation surgery, percutaneous endoscopic lumbar discectomy, and minimally invasive fracture reduction and fixation. Subsequently, with the development of an aging population and changes in the spectrum of orthopedic diseases, the company gradually developed a product matrix adapting to clinical indications in all orthopedic fields. Currently, the company's products cover the orthopedic spine, trauma, joint, sports medicine, and wound repair areas for postoperative wound healing. As of the date of the prospectus signing, the company and its subsidiaries have a total of 132 product registrations or approvals, including 62 Class I product registrations, 34 Class II product approvals, 35 Class III product approvals, and 1 registration of imported medical devices. According to data from the Medical Device Union, in 2023, the company ranks third among domestic manufacturers of spinal vertebral augmentation systems and sixth among domestic manufacturers of spinal implant medical devices. As one of the early entrants in the orthopedic market in China, AiDe Technology has always been committed to providing quality and affordable products, focusing on the layout in the grassroots medical market to promote the widespread use of cost-effective orthopedic medical devices, making high-quality medical products and services available to a wider range of regions and populations. The company's main products have gained a good reputation among customers after years of development and accumulation, establishing a strong brand influence and leading in the field of minimally invasive clinical treatment of spine. The company has been awarded honors such as "Suzhou City Level Enterprise Technology Center," "High-Tech Enterprise," and "Jiangsu Provincial Specialized and New Small and Medium-sized Enterprise." The company's vertebral augmentation surgery system and external fixation bracket have both been awarded the honor of "Suzhou Famous Brand Products." According to the prospectus, after deducting the issuance expenses, the raised funds will be invested in the following projects: Financially, in the fiscal years of 2022, 2023, 2024, and January to June 2025, the company achieved operating income of approximately 286 million yuan, 262 million yuan, 275 million yuan, and 149 million yuan respectively. During the same periods, the net profits were approximately 93.3894 million yuan, 63.5686 million yuan, 66.7902 million yuan, and 38.223 million yuan respectively.